RAHWAY, N.J. -- (BUSINESS WIRE)-- Merck (MRK), known as MSD outside of the United States and Canada, will hold its second-quarter 2025 sales and earnings conference call with institutional ...

Merck KGaA has reached an agreement with SpringWorks on a $47-per-share takeover deal that values the US biotech at $3.9 billion.

Review the current Merck & Co Inc (MRK:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if MRK is the best investment for you.

Merck KGaA is talking to SpringWorks about a takeover, and FDA approval for a neurofibromatosis drug could have sweetened any potential deal.

Get the latest Merck & Co., Inc. (MRK) stock news and headlines to help you in your trading and investing decisions.

Get the detailed quarterly/annual income statement for Merck & Co., Inc. (MRK). Find out the revenue, expenses and profit or loss over the last fiscal year.

Merck KGaA has concluded the previously announced acquisition of SpringWorks Therapeutics for an enterprise value of €3bn ($3.4bn).

Merck & Co., Inc. (MRK) latest earnings report: revenue, EPS, surprise, history, news and analysis.